David is an entrepreneur and technology innovator. He is known for pioneering the fields of A.I.-based medical decision-support, Training Analytics, and Virtual Patient Simulation (VPS).

David’s last company, TheraSim, launched the world’s first successful online VPS system for physicians and trained over 500,000 doctors in every country on Earth. TheraSim built the world’s largest network of computer-based clinical simulation sites in Africa in support of the USAID and the CDC’s HIV-treatment effort. TheraSim was acquired by WebMD in 2014.

Since then, he has focused his passion for technological innovation and learning systems in the field of clinical trials, helping sponsors make their studies more accurate and efficient through finding the right technology mix such as virtualization, performance management and applied behavioral sciences to produce the most effective, lasting, and engaging results for clinical trials.

David has always valued the interconnectedness of our vastly changing world, and has traveled to over 70 countries for his global health work and for cultural development outreach through music.

Michael is an adept leader, critical strategist and ambitious executive who is here to drive Pro-ficiency’s strategic objectives and fuel growth. With his extensive experience in startups, turnarounds and Fortune 100 companies, Michael naturally cultivates world-class management teams, resulting in smarter, faster, and more effective organizations.

While Michael currently hails from Colorado, a piece of his heart will always be in Kansas with his alma mater, the University of Kansas Jayhawks.

As a partner, Mr. Sorensen has extensive investment experience. He is responsible for transaction origination and execution, portfolio company value creation initiatives, investment policy, and investor relations. He is also a member of the Private Equity investment committee.

Prior to NovaQuest Capital, Mr. Sorensen was a director in BlackRock’s private equity group. In that role he was responsible for making investment decisions in a wide variety of geographies and industries, including healthcare, technology, and consumer/retail, among others.

Prior to BlackRock, Mr. Sorensen worked at Sorenson Capital (no familial relation), a mid-market private equity firm based in Salt Lake City. Similar to his current role, he analyzed private companies in a wide range of industry sub-sectors and geographies. Mr. Sorensen also worked as a consultant for L.E.K. Consulting in Los Angeles, where he worked closely with clients’ senior management on projects that included asset optimization, strategic planning, and customer segmentation, primarily in the healthcare and media industries.

As Partner, Mr. Davenport has extensive executive experience in building and transforming healthcare technology and services companies. He is responsible for transaction origination and execution, portfolio company value creation initiatives, and investment policy. Mr. Davenport is a member of the Private Equity investment committee.

Before joining NovaQuest Capital, Mr. Davenport was CEO and Board Member at Medfusion. He was instrumental in the carve-out of the company from Intuit and returning its core portal solution to a market leadership position.

Prior to Medfusion, Mr. Davenport was Chairman and CEO of Medquist, a leader in transcription services before and after the privatization of the company. Mr. Davenport facilitated a transformation of the business through the acquisition of a speech technology company, rebranding the company M*Modal and leading the take-private process.

Mr. Davenport’s previous experience also includes his time as President, Allscripts; CEO, Misys Healthcare; GM & EVP, Kodak Health Group (now Carestream Health), and executive leadership roles at Siemens and Shared Medical Systems. Mr. Davenport started his career at IBM where he spent 11 years in sales, sales leadership, and executive management positions.

As CEO of JTH Consulting, LLC., Jeanne commands broad knowledge and deep expertise in the Life Sciences arena. She also provides advisory services and consultation in support of global and domestic growth strategies for both for-profit and non-profit organizations in the life sciences, clinical research, eClinical, site development and pharmaceutical development markets. She is a NED and external BOD member for life sciences, eClinical, CDMO, pharmaceutical services, medical imaging, and biotechnology companies. She has dedicated much of her career to guiding international companies through healthy growth – thoughtfully, strategically, and with unyielding integrity.

She holds a bachelor’s degree of science from the University of Michigan and a master’s degree in business administration from the University of Michigan, Ross School of Business. She has over sixteen years of experience of working with IQVIA (formerly known as Quintiles, Inc.). She has also been associated as the chief executive officer of Ora, Inc. in the past as well as the chief operating officer of MEDIAN Technologies.

Robin Newman MSN EdD CPNP is the Global VP for Clinical Affairs at Beckman Coulter Diagnostics and Life Sciences. She holds both Bachelor and Master degrees in Nursing from the University of Texas at Austin and Arlington, and a doctorate in Human & Organizational Learning and Development from The George Washington University.

For more than 25 years, Dr. Newman has dedicated her career to building better futures for patients through developing healthcare solutions in the medical device and biopharmaceutical industries. Prior to joining Beckman Coulter, Robin served as the WW VP for Clinical Affairs and WW Vice President, Clinical, Preclinical and Medical Strategic R&D at Johnson & Johnson, the Director of the Office of Compliance at the Center for Devices and Radiological Health, US Food & Drug Administration, VP Quality, Regulatory, and Clinical Affairs at Siemens Healthcare Diagnostics, and Founder and CSO of MedTrials, a clinical research and regulatory consulting firm headquartered in Dallas, Texas.

Dr. Newman has her research roots firmly planted in the healthcare industry, beginning as a Clinical Research Coordinator in the Operating Room at Baylor University Medical Center, and a Senior Research Associate and Pediatric Nurse Practitioner in Pediatric Cardiology at the University of Texas Southwestern Medical School. She was honored as a Distinguished Alumni by the University of Texas at Arlington and served as a member and former Chairman of the Board of Trustees for the Association of Clinical Research Professionals.

Dr. Jeff Kasher is a known pharmaceutical development change expert with 28 years of experience at Eli Lilly. He is passionate about improving outcomes, bringing patients and research sites into the development process, and dramatically decreasing time to market. Jeff’s expertise includes novel product development for bench through market launch, research and clinical trial leadership, innovation center start-up as well as new industry paradigm creation.

Currently, Jeff serves as the President of Patients Can’t Wait, and is an Advisory Board member for Be the Partner, BlueCloud, and Wake Forest masters in clinical research management program. He advises several multinational Pharmaceutical companies and CROs, and emerging technology companies, and serves on the Board of Catalyst Clinical Research. He has been named one of the CenterWatch “20 Innovators Changing the Face of the Clinical Trials Industry.”

Jeff received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral fellowship in Physiology at Yale University School of Medicine.